Checkpoint inhibitors are an exciting therapy across a range of cancer types. Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Maud Toulmonde, MD, of the Institut Bergonié, Bordeaux, France, discusses the PEMBROSARC trial (NCT02406781), which investigated the use of pembrolizumab plus metronomic cyclophosphamide in advanced sarcoma.
PEMBROSARC: pembrolizumab combinations for advanced sarcoma
